A Review of Depression in the Emergency Department

EXECUTIVE SUMMARY

• Depression is a clinical diagnosis that must be present for at least two weeks. It may be associated with suicidal thoughts.
• Antidepressants generally are started by outpatient physicians, but they can be started in the emergency department if there is communication with an outpatient physician.
• SNAGGLE is a mnemonic for serotonin syndrome, which can be seen after overdose (monoamine oxidase inhibitors) or with a combination of medications.
• There is mounting evidence that ketamine and esketamine can safely and rapidly reduce suicidal ideation and diminish symptoms of depression.
• Consider depression screening in patients with low acuity or otherwise unidentified somatic complaints.
• Assessment of suicide risk in the emergency department is fraught with complexity.

Depression is a multifaceted recurrent disease of growing prevalence. The World Health Organization World Mental Health survey found the lifetime prevalence of depression to be 14.6% in high income countries and 11.1% in low-middle income countries.¹ The prevalence of depression increases with age; a meta-analysis of 48 studies from across the world found a 28.4% prevalence of depression in adults 60 years of age or older.²

Although the formal diagnosis of depression seldom is made in the emergency department (ED), emergency clinicians benefit from understanding the nature of depression and being prepared to deal with its complications, including suicidality and the toxicity of many antidepressant medications. When depression is not the primary driver of an ED visit — as opposed to the patient who has attempted suicide — it may present as either an underlying feature or a masking element of many vague and puzzling conditions.

Along with discussing the differential diagnosis and treatment modalities of depressive disorders, this article looks at the potentially groundbreaking role of ketamine and esketamine in acutely reducing suicidal ideation. This article will examine the conundrum of suicide risk assessment and review the toxicity of traditional antidepressant medications, highlighting the syndrome of selective serotonin reuptake inhibitor (SSRI) withdrawal — a condition that is easy to miss on initial presentation.

The Nature of Depression

Owing to the universal human emotion of sadness, clinicians all are personally familiar with the general symptoms of depression, such as apathy, fatigue, irritability, and anhedonia. The line between normal, everyday sadness and pathologic clinical depression can be subtle and variable — an issue of degree more than quality. The question of why people sometimes slide from normal sadness into debilitating states of depression is an ancient one.

Hippocrates (450 to 357 BCE), who described patients with an aversion to food, feelings of despondency, difficulty sleeping, restlessness, and irritability, posited a biochemical explanation. He wrote that black bile (melancholia) is secreted by the spleen in excessive amounts under the influence of Saturn. It then circulates and darkens the brain. He noted that patients with longstanding fearfulness were prey to melancholia.

Galen and medieval Persian physicians offered theories involving cerebral pathology and natural balance gone awry.³ Galen also observed that too much wine, too much passion, and too little sleep could breed a discontent with living, a hatred of others, and the desire to die.⁴

Modern Classification of Depressive Disorders

Given that psychiatric nomenclature is under continuous evolution, branching, and debate — The Diagnostic and Statistical Manual of Mental Disorders [DSM] is growing larger with each edition — the current classification and diagnostic criteria for depression warrant a brief discussion here.⁵ The National Institute of Mental Health (NIMH) considers the terms depression, major depressive disorder, and clinical depression to be interchangeable.⁶ Other synonymous terms found in the literature include unipolar depression and major depression.⁷ For clarity’s sake, this article will use the term major depressive disorder (MDD).

The diagnosis of depression requires the presence of depressed mood or anhedonia (loss of interest or pleasure) along with four or more of the following symptoms: suicidal ideation (with or without a plan); insomnia, early awakening, or hypersomnia; psychomotor retardation; agitation and restlessness; fatigue and loss of energy; feelings of worthlessness; a free-floating sense of guilt; significant weight loss or weight gain; and difficulty concentrating.

Additionally, to support a diagnosis of MDD, these symptoms must not be attributable to a substance use disorder or a major medical condition and must represent a challenge to the patient’s normal level of function.⁸ (See Table 1.)

The DSM-5, released in May 2013, describes these additional depressive disorders (see Table 2):^6,8

Persistent Depressive Disorder. Also referred to as dysthymia, this condition involves a continuous depressed mood lasting longer than two years during which patients may or may not have episodes of MDD.

Postpartum Depression. This is not the typical “baby blues” that affects many mothers and involves minor depression or anxiety symptoms, usually clearing within two weeks post-delivery. True postpartum depression displays the much more significant symptom pattern of MDD. Risk factors include prior history of depression, younger age, domestic abuse, and lower socioeconomic situation.

Psychotic Depression. Patients with MDD accompanied by psychotic features, such as delusions (frequently of guilt, poverty, or illness) or hallucinations, are classified as having psychotic depression.

Seasonal Affective Disorder. This condition involves the predictable, recurrent onset of MDD symptoms during the winter months.

The DSM-5 also introduced two new depressive disorders:

Disruptive Mood Dysregulation Disorder. This diagnosis is applied to children between the ages of 6 and 18 years of age who display persistent irritability and episodes of out-of-control behavior, and who previously were included in the category of bipolar disorder.

Premenstrual Dysphoric Disorder. This diagnosis applies to women who experience potentially disabling affective lability and other severe depressive symptoms during the last week of the luteal phase.

The DSM-5 also adds two specifiers allowing psychiatrists to detail a patient’s condition further. MDD “with mixed features” indicates that the patient has some manic features, which do not reach the threshold of full-blown mania; MDD “with anxious distress” specifies that the patient’s level of anxiety is such that additional treatment with specific anti-anxiety medication may be indicated.

The DSM-5-TR (text revision) was released in March 2022 and includes a newly described entity in the differential diagnosis for MDD — prolonged grief disorder — which involves persistent (longer than 12 months) severe feelings of distress and longing after the death of a person close to the sufferer.^9,10

Differences Between MDD and Bipolar Disorder

MDD and bipolar disorder constitute the two major human mood disorders. Bipolar disorder involves a cycling of mood states between mania (characterized by elevation, irritability, and expansiveness that lasts more than a week) and depression.

Bipolar disorder is divided further into several subclasses. Bipolar type I involves episodic mania that may or may not be interwoven with periods of MDD. Bipolar type II is defined as having spells of milder mania (hypomania) cycling with episodes of more significant depression.

Cyclothymia refers to a condition of recurrent hypomania alternating with milder depression (dysthymia).^4,7 These diagnoses will not be made in the ED. Emergency clinicians simply need to appreciate the fact that mood disorders represent a multidimensional continuum of characteristics.

Etiology and Pathophysiology

Although the ultimate cause of depression is unknown, the effectiveness of certain antidepressant medications suggests that a dysregulation of monoamine neurotransmitters (serotonin, norepinephrine, dopamine) and/or their receptors plays a major role. Anatomic changes in a number of brain structures, such as the hippocampus, amygdala, anterior cingulate cortex, and prefrontal cortex, may play a role.¹¹

Based on twin and adoption studies, there is a 30% to 40% genetic influence on the development of MDD.¹² The remaining depression cases appear to be related to environmental, psychosocial, physiologic, and epigenetic elements.

Medications, including proton-pump inhibitors and beta-blockers, have been implicated in the induction of depression. In a recent representative cross-sectional study of more than 26,000 adults, 9.5% were taking three or more concurrent medications, excluding psychotropic agents, that listed depression as a potential side effect. Of that group, the prevalence of depression was more than three times as great as in those not using such medications.¹³

Risk factors for developing MDD include low social support, divorce, substance use disorder, and chronic medical conditions.^14,15 The process may be bidirectional in that patients with MDD appear to have a higher risk of developing diabetes and coronary artery disease and a lowered pain tolerance.¹⁶

Adverse events in childhood, including physical and sexual abuse, increase the risk of an individual developing MDD, possibly by permanently altering corticotropin-releasing cells in the hypothalamus, causing exaggerated responses to future stress.^7,17

Epidemiology

Estimates of depression’s societal impact are staggering. At one time or another, depression may affect as much as 10% of the population worldwide, or about 300 million people, and is a leading cause of disability.^18,19 Estimates indicate that about half of all cases of depression are undetected or not adequately controlled.⁴ The ratio of females to males affected is approximately two to one.³

In contrast, bipolar disorder affects males and females in equal proportion. Although bipolar disorder tends to begin in an individual’s 30s, the onset of MDD occurs in the 40s, on average. Approximately half of all cases of MDD involve patients with underlying bipolar disorder.⁴

Suicide is the second most common cause of death in people between 10 and 24 years of age, and it results in more than 5,000 deaths each year in the United States.²⁰ Anywhere from 50% to 75% of suicides are related to depression.

Differential Diagnosis

Many factors can generate mood alterations and psychomotor change that resemble the symptoms of primary MDD. These situations include substance use disorders, corticosteroid use, central nervous system (CNS) infections, hyperthyroidism and hypothyroidism, hypoglycemia, and many others.⁷ Elderly patients, especially those with a new onset of depressive symptoms, require careful screening for occult infections or metabolic and endocrine derangements.

Chronic illness can trigger an episode of MDD. Conversely, MDD sometimes may manifest in the form of multiple unexplained somatic complaints.²¹ In a recent study, researchers showed an association between repeated ED visits for unexplained abdominal pain and moderate to severe depressive disorder.²² Consider screening for depression in such patients, who often receive multiple, resource-intensive, negative workups over the course of months and years.

In one study, patients with non-ST-segment elevation myocardial infarction and unstable angina who screened positive for depression spent an average of five hours longer in the ED.²³ The investigators speculated that this effect may be related partly to the fact that symptom patterns in patients with depressive disorder can be clouded by the depressive symptomatology.

Treatment of Depression

Traditional Antidepressant Medications

Modern pharmacologic treatment for depression dates back to the early 1950s, when researchers noticed that certain new antituberculosis agents that possessed monoamine oxidase inhibitory properties appeared to alleviate depressive symptoms.²⁴ Investigators speculated that this salutary effect might be due to a bump in monoamine neurotransmitters (serotonin, norepinephrine, dopamine) at CNS synapses. A flood of subsequent research resulted in the development of several generations of continually safer agents that enhance the synaptic availability of monoamine neurotransmitters.

These traditional antidepressant medications (TADMs) fall into the following categories: monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), tetracyclic antidepressants (TeCAs), selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), and atypical antidepressants.⁶ (See Table 3.)

Hundreds of clinical trials since the 1950s have demonstrated that TADMs relieve symptoms of depression to an extent 20% to 30% greater than placebo.²⁵ The beneficial effect appears stronger in moderate to severe depression than in milder forms.²⁵ The choice of an optimal agent for a given patient involves a knowledge of side effects, interactions, and comorbidities, and often involves a period of trial and error.²⁶ Some TADMs have indications for other conditions, including chronic pain and anxiety disorder.

Currently, TADMs seldom are initiated by emergency clinicians, partly because most are neither trained in making the initial diagnosis nor familiar with the ideal TADM for a given patient. SSRIs generally require two weeks to become effective, and patients need primary care physician (PCP) or psychiatry follow-up for dosage adjustment and to monitor for side effects, including the potential for a transient increase in suicidal ideation. However, given the excellent therapeutic to toxicity ratios of SSRIs and SNRIs, certain patients might benefit from having such medications started in the ED.

For an emergency clinician to initiate TADM treatment prior to discharge, the following conditions should be met: 1) medical causes of depressive symptoms have been ruled out; 2) the patient has been screened for suicidality and found to be at low to no risk; 3) there are no concurrent medications with potential adverse reactions (especially serotonin toxicity); and 4) the emergency physician has spoken with the follow-up PCP or psychiatrist, who is aware of the medication and agrees to follow up in a specified time frame, ideally a week or less.

The initial medication usually selected for a patient with straightforward MDD will be an SSRI, such as paroxetine.²⁶ For an adult, the starting dose of paroxetine is usually 20 mg, once a day, taken in the morning. Dosages will be increased weekly as needed in increments of 10 mg, up to a maximum of 50 mg per day.

For patients who have a chronic pain syndrome along with MDD, SNRIs often are the initial TADM.²⁶ Venlafaxine is a representative SNRI and can be initiated at 25 mg three times per day, with upward titration begun by the follow-up physician in approximately one week. Patients with MDD and anxiety symptoms often are started on either an SSRI or an SNRI.²⁶

In the face of worsening depression symptoms or SSRI withdrawal symptoms (discussed later), it also would be reasonable for an emergency physician to consider restarting a well-tolerated antidepressant that a patient recently had stopped taking on his or her own.⁷

Complications of Traditional Antidepressant Medications

Toxicity

Emergency clinicians in practice for more than a couple of decades will recall treating many cases of serious and often fatal TCA overdose. Patients would be awake and cooperative, then rapidly deteriorate, becoming obtunded and developing difficult-to-manage tachydysrhythmias and bradydysrhythmias with widening QRS and QT intervals. The scenario would be complicated by refractory hypotension and seizures. TCAs still are in use, and examples include amitriptyline, used primarily as an adjunct for the treatment of chronic pain and recurrent migraines, and clomipramine, which has an indication for obsessive compulsive disorder.

Emergency providers continue to see occasional overdoses with these agents and must be aware of the classic presentation and pharmacologic mechanisms, which include the inhibition of norepinephrine and serotonin uptake, alpha-adrenergic blockade, a quinidine-like action on myocardial cells, along with strong anticholinergic properties.²⁷ Always consider TCA toxicity in overdose patients with obtundation and widening QRS complexes.

Obtain early airway control, consider activated charcoal if less than one hour after ingestion, use benzodiazepines for seizures, and administer sodium bicarbonate for rhythm control, whether acidosis is present or not. Avoid antiarrhythmics that block sodium channels, such as the class Ia agents (procainamide, quinidine, disopyramide) and class Ic (flecainide). Class II agents can worsen hypotension, and class III agents (amiodarone) can further prolong the QT interval. Lidocaine (class Ib), despite its effect on sodium channels, has properties that make it the best agent for arrhythmias that do not respond to sodium bicarbonate alone.²⁷

The strong anticholinergic effects of the TCAs lead to profound CNS effects and an initial tachycardia. The use of physostigmine has been shown to be beneficial in anticholinergic agent poisoning, reducing the need for intubation. However, its use in TCA overdose, especially if there is any sign of sodium channel blockade with QRS prolongation, is highly problematic and may lead to cardiac decompensation.²⁸ By general consensus, physostigmine should be avoided in suspected TCA overdose, unless expert toxicology consultation is available.

TeCAs have a toxicity profile similar to the TCAs, although significantly milder. Mirtazapine is among the most commonly prescribed TeCAs and often is used for depression accompanied by insomnia and anxiety. In overdose, the TeCAs have strong antihistaminic effects but are markedly less toxic than the TCAs and seldom cause cardiovascular issues. The overdose fatality rate of TeCAs is similar to that of the SSRIs.

The original class of antidepressant medications, MAOIs, still is used in the treatment of certain cases of resistant MDD, atypical depression, panic disorder, social phobia, and other conditions.²⁹ Although effective, they have fallen out of favor because of widespread drug-drug interactions and dietary restrictions.

Patients taking MAOIs can experience severe hypertensive crises when ingesting the tyramine contained in aged cheeses, beer, wine, and animal liver. Adverse reactions, including serotonin syndrome (discussed more later), can occur when patients taking MAOIs are exposed to other classes of antidepressants, as well as St. John’s wort, tryptophan, L-Dopa, meperidine, tramadol, dextromethorphan, MDMA, and various adrenergic stimulants. MAOI-induced hypertensive crisis can occur in patients taking alpha-2 agonist medications for glaucoma.³⁰

Because of a much safer therapeutic to toxicity ratio, the SSRIs and SNRIs have become the predominant TADMs currently prescribed. Adverse effects are less common with these agents than with any other class of TADM. Side effects generally are mild and include headache, insomnia, restlessness, initial anxiety, and possible sexual dysfunction. Nausea, insomnia, dry mouth, and sometimes hypertension are more likely to be seen with the SNRIs than with the SSRIs.³¹

SSRI/SNRI overdose is rarely fatal. Most cases of serious toxicities involve multi-substance ingestions.^32,33 There is evidence suggesting that the SNRI venlafaxine may be more likely to cause adverse cardiac effects than SSRIs.³⁴

Abrupt cessation of treatment with SSRIs and SNRIs can cause a well-recognized withdrawal syndrome that begins within several days of discontinuation and may last two or more weeks and sometimes much longer.³⁵ Be aware that the clinical picture includes flu-like symptoms, headache, ataxia, tremors, nausea, diarrhea, possible auditory and visual hallucinations, confusion, electric shock sensations, and vivid dreams.³⁵ Symptoms are not as prominent with longer-acting agents like fluoxetine.

Researchers have studied the phenomenon in intensive care unit patients and have concluded that home TADM regimens should be continued in critically ill patients to avoid the added symptom burden.³⁶ Strategies to avoid or minimize the SSRI/SNRI withdrawal syndrome include gradual tapering, switching to a longer-acting agent before discontinuation, and the temporary reinstitution of the SSRI/SNRI followed by a slow taper.³⁷ (See Table 4.)

Bupropion, trazodone, and mirtazapine are among the TADMs classified as atypical antidepressants, and each has unique mechanisms of action that modulate monoamine neurotransmitters and/or receptors. Indications for bupropion, a dopamine and norepinephrine uptake inhibitor, include depression and smoking cessation. With more sedating properties than other TADMs, trazodone, a potent serotonin and alpha-2 antagonist, is a preferred agent by some clinicians for the treatment of insomnia instead of benzodiazepines.

Mirtazapine, an alpha-2 antagonist, also is useful for depression complicated by insomnia or anxiety. It stimulates appetite and weight gain, aids in sleep, and often is used in the elderly population.²⁶ Like the SSRIs and SNRIs, the therapeutic to toxicity ratio of the atypical agents is quite high.

Serotonin Syndrome

Serotonin syndrome, more usefully called serotonin toxicity, is a potentially fatal continuum of symptoms caused by an overactivation of peripheral and central postsynaptic serotonin receptors.^38,39 These symptoms include neuromuscular hyperactivity, autonomic excess, altered mental status, and gastrointestinal (GI) disturbance. In brief, too much serotonin can be dangerous, and a major excess can kill.^38,40,41

The long list of compounds that can raise serotonin levels includes SSRIs, SNRIs, MAOIs (including linezolid and methylene blue), opiates (tramadol, fentanyl, dextromethorphan), CNS stimulants, St. John’s wort, lithium, risperidone, olanzapine, and metoclopramide.^7,40

Although mild and moderate cases of serotonin syndrome have been reported with single agents (after overdose or rapid upward therapeutic titration of an SSRI, for example), severe serotonin toxicity typically is triggered by a combination of substances that activate serotonin receptors through different mechanisms (e.g., serotonin precursors, agonists, reuptake inhibitors, MAOIs). The worst cases frequently involve an MAOI plus something else.^38,41

Serotonin toxicity is a clinical diagnosis of exclusion, and its calling card is clonus. Spontaneous clonus alone, in the presence of known or suspected serotonin-raising chemicals, immediately narrows the differential. Serotonin toxicity tends to have an acute onset over hours and presents with the basic triad of neuromuscular symptoms (spontaneous clonus, induced clonus, ocular clonus, tremor, hyperreflexia, and possible rigidity); autonomic excess (hyperthermia, mydriasis, diaphoresis); and altered mental status (confusion, excitement, agitation, seizures). GI disturbances, such as nausea and diarrhea, also may occur.

The worst cases often are marked by rapidly rising temperature and rigidity.³⁸ Another characteristic feature is that the clonus and hyperreflexia are more noticeable in the lower extremities. Remember that serotonin toxicity represents a continuum, with mild symptoms ranging from irritability, brisk reflexes, tremors, and nausea all the way to delirium, hyperthermia, sustained clonus, rigidity, rhabdomyolysis, and death. (See Table 5.)

The Hunter Criteria for Serotonin Toxicity (HCST) currently is the diagnostic gold standard, with a sensitivity of 84% and a specificity of 97%.⁴⁰ HCST is positive if a patient has been exposed to a serotonergic agent and has at least one of the following features: spontaneous clonus, inducible clonus plus agitation or diaphoresis, ocular clonus plus agitation or diaphoresis, tremor and hyperreflexia, or hypertonia and fever > 38° C plus ocular or inducible clonus.⁴²

For the purposes of helping clinicians keep serotonin toxicity on the radar screen, remember the mnemonic SNAGGLE: sympathetic (autonomic) excess (fever, diaphoresis, tachycardia, mydriasis); neuromuscular hyperactivity (tremors, myoclonus, clonus, hyperreflexia, rigidity); altered mental status (excitement, restlessness, agitation, confusion); gastrointestinal upset (nausea, diarrhea); gait disturbance (and go look up the Hunter criteria); and LE, for the symptoms being more prominent in the lower extremities. (See Table 6.)

The differential diagnosis of serotonin toxicity includes neuroleptic malignant syndrome (NMS). However, unlike the more acute presentation of serotonin syndrome, NMS typically evolves over days, lacks the feature of clonus, and often is accompanied by extrapyramidal signs.³⁸ Other conditions to consider include anticholinergic toxicity, alcohol or benzodiazepine withdrawal, antidepressant discontinuation syndrome, meningitis/encephalitis, and malignant hyperthermia.⁴¹ (See Table 5.)

Mild and moderate cases of serotonin toxicity typically resolve within several days after discontinuing the agents involved. Patients with severe serotonin toxicity often require prolonged intensive care with intravenous hydration, benzodiazepine sedation, and active cooling. Complications include disseminated intravascular coagulation, rhabdomyolysis, adult respiratory distress syndrome, and multi-organ failure. A serotonin antagonist such as cyproheptadine often is used, but absolute evidence for its value is lacking.³⁸

Be aware that some sources list ondansetron, a serotonin 5-HT3 receptor antagonist, along with metoclopramide as antiemetics associated with serotonin toxicity. Although these concerns are based solely on a small number of case reports, benzodiazepines might be considered as an alternative antiemetic for patients with serotonin toxicity.^39,43-45

Ketamine/Esketamine for Depression and Suicidality

Ketamine and esketamine are high-affinity N-methyl-d-aspartate (NMDA) receptor antagonists with glutaminergic properties. A growing body of evidence suggests that subanesthetic doses of intravenous (IV) ketamine and intranasally administered esketamine are remarkably effective at rapidly ameliorating the symptoms of MDD (including treatment-resistant depression) and in acutely reducing suicidal ideation, while presenting a generally good safety profile.^46-56 Effects may be seen in an hour or less.

In one study, 33 patients with depression were administered a 0.5 mg/kg ketamine infusion. The investigators measured a significant decrease in all the employed suicide risk scales at 40 minutes.⁵⁷ Another study performed in a military ED showed dramatic decreases in suicidality within 40 minutes after an infusion of 0.2 mg/kg ketamine vs. no change in placebo controls.⁵⁸ In one randomized controlled trial, patients with treatment-resistant depression were given single doses of either ketamine or midazolam. Approximately half of the ketamine group had suicide scales of zero at 24 hours compared to one-quarter of the midazolam group.⁵⁹

The American Psychiatric Association found enough evidence to warrant a 2017 consensus statement noting that ketamine produces a rapid and potent antidepressant effect in patients previously resistant to treatment.⁶⁰ To judge by the increasing number of outpatient clinics that provide off-label low-dose ketamine infusions for the treatment of depression (along with other conditions including PTSD, chronic pain, and migraines), public acceptance may be outpacing its use in some traditional clinical settings.

Ketamine and esketamine also have activating effects upon opioid receptors. One recent small and intriguing trial suggested that ketamine’s opioid receptor properties may be involved in its antidepressant effects.⁶¹ The investigators pretreated a group of depressed subjects with naloxone prior to administering ketamine and discovered a markedly attenuated antidepressant response.

Although ketamine is not yet Food and Drug Administration (FDA) approved for the treatment of psychiatric disorders, its off-label use for various psychiatric conditions is growing more widespread, owing in part to the proliferation of ketamine-infusion clinics that operate legally under state statutes.⁶² Nasal spray esketamine, however, was separately granted FDA approval in 2019 as a Schedule III controlled substance for the treatment of treatment-resistant depression.

Although more large-scale ED-based studies are needed, it is not difficult to imagine an ED patient with MDD and suicidality being administered one of these agents (in close consultation with an experienced psychiatrist who can help provide follow-up), then being discharged home after careful re-evaluation. Ketamine’s long positive safety record in the ED as a procedural sedation agent is reassuring.⁶³

Non-Pharmacologic Treatments for Depression

Cognitive behavioral therapy (CBT) is a well-studied treatment modality for patients with depression. For many patients, it can be an effective stand-alone treatment, or it can serve as a useful adjunct with antidepressant medications.⁶⁴ CBT aims to help individuals identify cognitive distortions and maladaptive behaviors and to replace them with more positive habits, skills, and coping strategies. Some authors consider CBT to be the gold standard for modern psychotherapy, and to be useful in treating many conditions other than depression, including PTSD, eating disorders, substance use disorders, and borderline personality disorder.⁶⁵

Electroconvulsive therapy (ECT) is a safe and time-tested treatment for individuals with MDD who have failed other forms of treatment. ECT also can be efficacious for other disorders, including catatonia and treatment-resistant schizophrenia.⁶⁶ The mechanism by which inducing a seizure can ameliorate psychiatric conditions is not fully understood, but it may involve changes in regional cerebral blood flow, transient breaches in the blood-brain barrier, and neurochemical release and metabolism.⁶⁶ The need for a backup treatment modality such as ECT remains significant. Approximately two-thirds of patients in one series did not respond to a three-month regimen of antidepressant medication, and approximately half of the patients in another study who did not respond to antidepressants also did not respond to CBT.^67,68

Transcranial magnetic stimulation (TMS) involves a noninvasive exposure of areas of the brain to a changing magnetic field that induces current flow via electromagnetic induction within the tissue thus exposed. There is substantial evidence that it can be effective in improving the symptoms of treatment-resistant depression, with minimal side effects. TMS also appears to be useful in patients with neuropathic pain.^69,70 As is the case with ECT, a precise biochemical explanation for its efficacy still is unknown.

Herbal medications (particularly St. John’s wort) have long been touted for the treatment of various psychiatric disorders, including MDD, anxiety, and insomnia, and researchers have explored possible neuropharmacologic mechanisms.^71-74 A recent systematic review of 35 efficacy studies found evidence that St. John’s wort is superior to placebo in the treatment of mild to moderate depression, and that it is neither superior nor inferior to the standard antidepressants, although with fewer adverse effects.⁷⁵ However, there was considerable heterogeneity among the studies reviewed, and data were lacking to allow conclusions regarding its value in treating severe depression.

Suicide Risk Assessment

Screening for Depression and Suicidality

A significant public health problem across the world, suicide has become the third leading cause of death among adolescents 14 to 19 years of age in the United States, the second leading cause of mortality among young adults 20 to 29 years of age, and the fourth leading cause of death for those between 10 to 65 years of age.^76-79 Evidence suggests that a disproportionate percentage of patients who attempt suicide have had an ED visit within the prior year, whereas no such correlation was found with primary care visits or hospitalizations.⁷⁸ Patients who are experiencing both severe anxiety and depression may visit the ED at twice the normal rate.⁸⁰

According to data from the National Hospital Ambulatory Medical Care Survey, between 2002 and 2008, an increasing percentage of patients with depression and suicidality presented to EDs rather than to outpatient clinics. Additionally, there is evidence that some patients presenting to the ED with low-acuity complaints and otherwise unidentified somatic complaints will screen positive for occult depression and suicidality, and that many patients desire to address these issues when identified.^81,82

Given that the prevalence of depression and suicidality appears to be substantially higher in the ED than elsewhere, should emergency providers be screening for it more aggressively? In a study performed at an urban ED that has 80,000 annual visits, investigators screened 816 patients who presented with unrelated low-acuity chief complaints with one of two previously validated screening tools, the Patient Health Questionnaire for Depression and Anxiety (PHQ-4) and the Suicide Behaviors Questionnaire-Revised (SBQ-R). Of those 816 patients who presented for issues ostensibly unrelated to depression or suicidality, 11% screened positive as high risk for suicide.⁸² Of those patients, a significant proportion were interested in addressing these issues during their ED stay. However, the ultimate effect of this finding remains to be explored.

Nowhere is suicide more tragic than in adolescents. A recent, small study showed the possible effectiveness of an intervention for adolescents at risk for suicide.⁷⁷ Forty-nine adolescents between 14 and 17 years of age who had presented to the ED for unrelated complaints screened positive for suicide risk because of depression and alcohol use disorder or recent suicidal ideation or attempts. They were randomized into either a brief ED-based, personalized counseling intervention known as Teen Options for Change (TOC) or treatment as usual. At the two-month follow-up, the TOC group showed a larger decrease in depression scores.

Much work is needed to determine what resources are required for such screening programs, what interventions could be mobilized, and what benefits may accrue. Such efforts would need to include logistical support for emergency physicians because a majority do not feel confident in their ability to create safety plans for depressed and suicidal patients.^83,84

For a valuable in-depth discussion of suicide assessment and disposition, please refer to the Jan. 1, 2019, issue of Emergency Medicine Reports.⁸⁵

Predicting the Risk of Suicide

Predicting the risk of suicide is challenging for both mental health professionals and emergency physicians. Factors that increase the risk include: suicidal intent and a plan; a history of attempts; a family history of suicide; recent stressors; and lack of social supports. Additional risk factors include a history of alcoholism or other substance use disorder, a chronic illness, age younger than 19 years or older than 45 years, current depressive symptoms, male sex, the contemplation of a highly lethal method of committing suicide, and a history of schizophrenia or bipolar disorder. (See Table 7.) Previous suicide attempts are highly predictive of future behavior.⁸⁶ The widely used SAD PERSONS Scale (SPS) incorporates these factors and provides a scoring scenario to help predict risk. The letters in the name of the scale stand for: sex (male > female); age (older white male at greater risk); depression; previous attempt; ethanol/other substance abuse; rational thinking loss; social support lacking; organized plan; no spouse; and sickness (medical or psychiatric). Five or more points on the scale may indicate a high risk of suicide.⁷

The use of the SPS by emergency physicians has shown some degree of concordance with subsequent psychiatric suicide risk assessments.⁸⁷ Other researchers suggest that the SPS may be fairly specific regarding the identification of patients at risk for self-harm events, but it has a suicide risk prediction sensitivity of less than 10%.⁸⁸

Assessment of suicide risk in the ED remains an individualized process fraught with complexity. Emergency physicians should be aware of an excellent, online clinical resource developed by the American College of Emergency Physicians (www.acep.org/icar2e) that provides concise information on suicide risk assessment, red flags, screening tools, and communication tips. Consider creating a shortcut to this resource on every ED computer desktop.

Summary

Depression is a worldwide public health problem. A disproportionate number of patients experiencing depression will be seen in EDs, many of them for unrelated medical issues. The diagnosis of depression requires the presence of depressed mood or anhedonia (loss of interest or pleasure) along with four or more of the following symptoms: suicidal ideation (with or without a plan); insomnia, early awakening, or hypersomnia; psychomotor retardation; agitation and restlessness; fatigue and loss of energy; feelings of worthlessness; a free-floating sense of guilt; significant weight loss or weight gain; and difficulty concentrating. One of the emergency physician’s major roles in the care of patients with depression is to search for treatable medical conditions, such as occult infections, endocrinological disease, and toxic/metabolic disturbances.

Treatment for depression includes antidepressant medications and cognitive behavioral therapy. Treatment-resistant depression may respond to a change in antidepressant medication, electroconvulsive therapy, or transcranial magnetic stimulation. Low-dose ketamine infusions and intranasal esketamine have efficacy in rapidly relieving suicidal ideation and MDD symptoms, which could decrease the suffering of many patients and lead to substantial costs savings by reducing the need for admissions and shortening hospital stays. The American College of Emergency Physicians has not yet published a position statement or guidelines regarding the use of ketamine or esketamine for depression and suicidal ideation. More ED-based studies are needed.

Combinations of serotonergic compounds commonly used for depression can trigger serotonergic toxicity, manifested by neuromuscular hyperactivity, autonomic excess, and altered mental status. Severe serotonin toxicity is life-threatening and usually is caused by the combination of an MAOI and another medication such as an SSRI that raises synaptic serotonin levels via a different mechanism.

Suicide risk assessment remains challenging, even for seasoned mental health professionals. Factors that raise the likelihood of a patient attempting suicide include male sex, history of previous attempts, positive family history of suicide, age younger than 19 years or greater than 45 years, history of alcohol or other substance use disorder, and the presence of a suicide plan of high lethality. The SAD PERSONS scale commonly used in EDs to evaluate patients at risk for suicide attempts is specific but poorly sensitive. The same appears to hold true for clinical judgment alone. Better tools are needed.

REFERENCES

1. Kessler RC, Bromet EJ. The epidemiology of depression across cultures. Annu Rev Public Health 2013;34:119-138.
2. Hu T, Zhao X, Wu M, et al. Prevalence of depression in older adults: A systematic review and meta-analysis. Psychiatry Res 2022;311:114411.
3. Sadeghfard A, Bozorgi A, Ahmadi S, Shojaei M. The history of melancholia disease. Iran J Med Sci 2016;41(3 Suppl):S75.
4. Akiskal HS. Mood disorders: Historical introduction and conceptual overview. In: Sadock BJ, Sadock VA, Ruiz P, eds. Kaplan & Sadock’s Comprehensive Textbook of Psychiatry. 9th ed. Lippincott Williams & Wilkins; 2009:1629-1645.
5. Regier DA, Kuhl EA, Kupfer DJ. The DSM-5: Classification and criteria changes. World Psychiatry 2013;12:92-98.
6. National Institute of Mental Health. Depression. Last reviewed September 2022. www.nimh.nih.gov/health/topics/depression
7. DeSelm TM. Mood and anxiety disorders. In: Tintinalli J, Stapczynski J, Ma O, et al, eds. Tintinalli’s Emergency Medicine: A Comprehensive Study Guide. 8th ed. McGraw-Hill; 2016:1963.
8. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. American Psychiatric Publishing; 2013.
9. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed., Text Revision (DSM-5-TR). American Psychiatric Publishing; March 16, 2022.
10. American Psychiatric Association. DSM-5-TR Update. Supplement to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision. American Psychiatric Association. September 2022. https://www.psychiatry.org/psychiatrists/practice/dsm/updates-to-dsm/updates-to-dsm-5-tr-criteria-text
11. Pandya M, Altinay M, Malone DA Jr, Anand A. Where in the brain is depression? Curr Psychiatry Rep 2012;14:634-642.
12. Hasler G. Pathophysiology of depression: Do we have any solid evidence of interest to clinicians? World Psychiatry 2010;9:155-161.
13. Qato DM, Ozenberger K, Olfson M. Prevalence of prescription medications with depression as a potential adverse effect among adults in the United States. JAMA 2018;319:2289-2298.
14. Kendler KS, Gardner CO, Prescott CA. Toward a comprehensive developmental model for major depression in men. Am J Psychiatry 2006;163:115-124.
15. Kendler KS, Gardner CO, Prescott CA. Toward a comprehensive developmental model for major depression in women. Am J Psychiatry 2002;159:1133-1145.
16. Katon WJ. Clinical and health services relationships between major depression, depressive symptoms, and general medical illness. Biol Psychiatry 2003;54:216-226.
17. Saveanu RV, Nemeroff CB. Etiology of depression: Genetic and environmental factors. Psychiatr Clin North Am 2012;35:51-71.
18. World Health Organization. The World Health Report 2001: Mental Health — New Understanding, New Hope. World Health Organization; 2001.
19. World Health Organization. Fact sheet on depression. Updated Sept. 13, 2021. https://www.who.int/en/news-room/fact-sheets/detail/depression
20. Babeva K, Hughes JL, Asarnow J. Emergency department screening for suicide and mental health risk. Curr Psychiatry Rep 2016;18:100.
21. Chang B, Gitlin D, Patel R. The depressed patient and suicidal patient in the emergency department: Evidence-based management and treatment strategies. Emerg Med Pract 2011;13:1-23.
22. Meltzer AC, Bregman B, Blanchard J. Depression is associated with repeat emergency department visits in patients with non-specific abdominal pain. West J Emerg Med 2013;15:325-328.
23. Edmondson D, Newman JD, Chang MJ, et al. Depression is associated with longer emergency department length of stay in acute coronary syndrome patients. BMC Emerg Med 2012;12:14.
24. Selikoff IJ, Robitzek EH. Tuberculosis chemotherapy with hydrazine derivatives of isonicotinic acid. Dis Chest 1952;21:385-438.
25. Penn E, Tracy DK. The drugs don’t work? Antidepressants and the current and future pharmacological management of depression. Ther Adv Psychopharmacol 2012;2:179-188.
26. Shultz E, Malone DA Jr. A practical approach to prescribing antidepressants. Clev Clin J Med 2013;80:625-631.
27. Giwa A, Oey E. The return of an old nemesis: Survival after severe tricyclic antidepressant toxicity, a case report. Toxicol Rep 2018;5:357-362.
28. Watkins JW, Schwarz ES, Arroyo-Plasencia AM, et al. The use of physostigmine by toxicologists in anticholinergic toxicity. J Med Toxicol 2015;11:179-184.
29. Cristancho MA, O’Reardon JP, Thase ME. Atypical depression in the 21st century: Diagnostic and treatment issues. Psychiatric Times 2011;28:42-47.
30. Bowling B. Kanski’s Clinical Ophthalmology: A Systematic Approach. 8th ed. Elsevier; 2016:332.
31. Santarsieri D, Schwartz T. Antidepressant efficacy and side-effect burden: A quick guide for clinicians. Drugs Context 2015;4:212290.
32. Barbey JT, Roose SP. SSRI safety in overdose. J Clin Psychiatry 1998;59 (Suppl 15):42-48.
33. Kaicker J, Bostwick J. Co-ingestion of tricyclic antidepressants with selective norepinephrine reuptake inhibitors: Overdose in the emergency department. Can Fam Physician 2016;62:485-489.
34. Bavle A. Venlafaxine induced QTc interval prolongation in a therapeutic dose. Asian J Psychiatr 2015;16:63-64.
35. Fava GA, Gatti A, Belaise C, et al. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: A systematic review. Psychother Psychosom 2015;84:72-81.
36. Bainum TB, Fike DS, Mechelay D, Haase KK. Effect of abrupt discontinuation of antidepressants in critically ill hospitalized adults. Pharmacotherapy 2017;37:1231-1240.
37. Wilson E, Lader M. A review of the management of antidepressant discontinuation symptoms. Ther Adv Psychopharmacol 2015;5:357-368.
38. Buckley NA, Dawson AH, Isbister GK. Serotonin syndrome. BMJ 2014;348:g1626.
39. World Health Organization. Ondansetron and serotonin syndrome. WHO Pharmaceuticals Newsletter 2012;3:16-21.
40. Volpi-Abadie J, Kay AM, Kaye AD. Serotonin syndrome. Ochsner J 2013;13:533-540.
41. Foong AL, Patel T, Kellar J, Grindrod KA. The scoop on serotonin syndrome. Can Pharm J (Ott) 2018;151:233-239.
42. Dunkley EJC, Isbister GK, Sibbritt D, et al. The Hunter Serotonin Toxicity Criteria: Simple and accurate diagnostic decision rules for serotonin toxicity. QJM 2003;96:635-642.
43. Vashistha V, Wang RZ, Kaur S, Rutecki G. In reply: Serotonin syndrome. Cleve Clin J Med 2017;84:342-343.
44. Rojas-Fernandez CH. Can 5-HT3 antagonists really contribute to serotonin toxicity? A call for clarity and pharmacological law and order. Drugs Real World Outcomes 2014;1:3-5.
45. Harada T, Hirosawa T, Morinaga K, Shimizu T. Metoclopramide-induced serotonin syndrome. Intern Med 2017;56:737-739.
46. Lee J, Narang, P, Enja M, Lippmann S. Use of ketamine in acute cases of suicidality. Innov Clin Neurosci 2015;12:29-31.
47. Derakhshanian S, Zhou M, Rath A, et al. Role of ketamine in the treatment of psychiatric disorders. Health Psychol Res 2021;9:25091.
48. Jollant F, Colle R, Nguyen TML, et al. Ketamine and esketamine in suicidal thoughts and behaviors: A systematic review. Ther Adv Psychopharmacol 2023;13:1-25.
49. Ballard ED, Ionescu DF, Vande Voort JL, et al. Improvement in suicidal ideation after ketamine infusions: Relationship to reductions in depression and anxiety. J Psych Res 2014;58:161-166.
50. Zarate CA Jr, Brutsche NE, Ibrahim L, et al. Replication of ketamine’s antidepressant efficacy in bipolar depression: A randomized controlled add-on trial. Biol Psychiatry 2012;71:939-946.
51. Genovese NR, Racine CW, Wolfrum LA. Intravenous ketamine as a treatment option for patients presenting to the ED with suicidal ideation. Am J Psychiatry Residents’ J 2022;17:2-13.
52. Maguire L, Bullard T, Papa L. Ketamine for acute suicidality in the emergency department: A systematic review. Am J Emerg Med 2021;43:54-58.
53. Feeney A, Papakostas GI. Pharmacotherapy: Ketamine and esketamine. Psychiatr Clin North Am 2023. Available online March 10, 2023. https://doi.org/10.1016/j.psc.2023.02.003
54. Domany Y, Shelton RC, McCullumsmith CB. Ketamine for acute suicidal ideation. An emergency department intervention: A randomized, double-bline, placebo-controlled, proof-of-concept trial. Depress Anxiety 2020;37:224-233.
55. Feeney A, Hock RS, Freeman MP, et al. The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study. Eur Neuropsychopharmacol 2021;49:122-132.
56. Canuso CM, Singh JB, Fedgchin M, et al. Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: Results of a double-blind, randomized, placebo-controlled study. Am J Psychiatry 2018;175:620-630.
57. DiazGranados N, Ibrahim LA, Brutsche NE, et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry 2010;71:1605-1611.
58. Burger J, Capobianco M, Lovern R, et al. A double-blinded, randomized, placebo-controlled sub-dissociative dose ketamine pilot study in the treatment of acute depression and suicidality in a military emergency department setting. Mil Med 2016;181:1195-1199.
59. Price RB, Iosifescu DV, Murrough JW, et al Effects of ketamine on explicit and implicit suicidal cognition: A randomized controlled trial in treatment-resistant depression. Depress Anxiety 2014;31:335-343.
60. Sanacora G, Frye MA, McDonald W, et al. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry 2017;74:399-405.
61. Williams NR, Heifets BD, Blasey C, et al. Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. Am J Psychiatry 2018;175:1205-1215.
62. Bricken H. The ketamine clinic craze: Legalities and possibilities. Psychedelics Law Blog. Last modified Jan. 30, 2023. https://harrisbricken.com/psychlawblog/the-ketamine-clinic-craze-legalities-and-possibilities/#page=1
63. Krystal JH, Sanacora G, Duman RS. Rapid-acting glutaminergic antidepressants: The path to ketamine and beyond. Biol Psychiatry 2013;73:1133-1141.
64. Driessen E, Hollon SD. Cognitive behavioral therapy for mood disorders: Efficacy, moderators and mediators. Psychiatr Clin North Am 2010;33:537-555.
65. David D, Cristea I, Hofmann SG. Why cognitive behavior therapy is the current gold standard of psychotherapy. Front Psychiatry 2018;9:4.
66. Singh A, Kar SK. How electroconvulsive therapy works: Understanding the neurobiological mechanisms. Clin Psychopharmacol Neurosci 2017;15:210-221.
67. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. Am J Psychiatry 2006;163:28-40.
68. Wiles N, Thomas L, Abel A, et al. Cognitive behavioral therapy as an adjunct to pharmacotherapy for primary care based patients with treatment resistant depression: Results of the CoBalT randomized controlled trial. Lancet 2013;381:375-384.
69. O’Reardon JP, Solvason HB, Janicak PG, et al. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: A multisite randomized controlled trial. Biol Psychiatry 2007;62:1208-1216.
70. Lefaucher JP, André-Obadia N, Antal A, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). Clin Neurophysiol 2014;125:2150-2206.
71. Liu L, Liu C, Wang Y, et al. Herbal medicine for anxiety, depression and insomnia. Curr Neuropharmacol 2015;13:481-493.
72. Vance KM, Ribnicky DM, Hermann GE, Rogers RC. St. John’s wort enhances the synaptic activity of the nucleus of the solitary tract. Nutrition 2014;30(Suppl):S37-S42.
73. Warren MB, Cowen PJ, Harmer CJ. Subchronic treatment with St. John’s wort produces a positive shift in emotional processing in healthy volunteers. J Psychopharmacol 2019;33:194-201.
74. Zirak N, Shafiee M, Soltani G, et al. Hypericum perforatum in the treatment of psychiatric and neurodegenerative disorders: Current evidence and potential mechanisms of action. J Cell Physiol 2018;234:8496-8508.
75. Apaydin EA, Maher AR, Shanman R, et al. A systematic review of St. John’s wort for major depressive disorder. Syst Rev 2016;5:148.
76. Rihmer Z, Németh A, Kurimay T, et al. [Recognition, care and prevention of suicidal behavior in adults]. [Article in Hungarian]. Psychiatr Hung 2017;32:4-40.
77. King CA, Gipson PY, Horwitz AG, Opperman KJ. Teen options for change: An intervention for young emergency patients who screen positive for suicide risk. Psychiatr Serv 2015;66:97-100.
78. Ballard ED, Cwik M, Storr CL, et al. Recent medical service utilization and health conditions associated with a history of suicide attempts. Gen Hosp Psychiatry 2014;36:437-441.
79. Chakravarthy B, Toohey S, Rezaimehr Y, et al. National differences between ED and ambulatory visits for suicidal ideation and attempts and depression. Am J Emerg Med 2014;32:443-447.
80. Abar B, Holub A, Lee J, et al. Depression and anxiety among emergency department patients: Utilization and barriers to care. Acad Emerg Med 2017;24:1286-1289.
81. Chang B, Gitlin D, Patel R. The depressed patient and suicidal patient in the emergency department: Evidence-based management and treatment strategies. Emerg Med Pract 2011;13:1-23.
82. McBride SM, Braz VA, Jones CW. Occult suicidality and psychiatric disease among emergency department patients with low-acuity chief complaints. West J Emerg Med 2018;19:573-578.
83. Hoyer D, David E. Screening for depression in emergency department patients. J Emerg Med 2012;43:786-789.
84. Olfson M, Marcus SC, Bridge JA. Focusing suicide prevention on periods of high risk. JAMA 2014;311:1107-1108.
85. Schears R, Schears M. Suicide assessment and disposition. Emerg Med Rep 2019;40:1-10.
86. Babeva K, Hughes JL, Asarnow J. Emergency department screening for suicide and mental health risk. Curr Psychiatry Rep 2016;18:100.
87. Chandramouleeswaran S, Edwin NC, Victor PJ, Tharyan P. The emergency physician’s assessment of suicide risk in intentional self-poisoning using the modified SAD PERSONS scale versus standard psychiatric evaluation in a general hospital in South India: A cross-sectional study. Trop Doct 2015;45:21-26.
88. Saunders K, Brand F, Lascelles K, Hawton K. The sad truth about the SADPERSONS Scale: An evaluation of its clinical utility in self-harm patients. Emerg Med J 2014;31:796-798.